All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
SubtypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2021-11-05T11:07:49.000Z

What does the future of T-cell lymphoma management look like?

By Camilla Rossi, Mark Maitland
Featured
Jia Ruan
Nov 5, 2021
Share:

Bookmark this article

During Lymphoma Leukemia & Myeloma 2021 Virtual Congress, the Lymphoma Hub was pleased to speak to Jia Ruan, Weill Cornell Medicine, New York, US. We asked, What does the future of T-cell lymphoma management look like?

What does the future of T-cell lymphoma management look like?

Ruan describes a promising future for T-cell lymphoma with increasingly personalized treatment, driven by precision medicine and a growing list of targeting agents. She outlines the current treatment approach, explains the impact of biological agents such as brentuximab, and describes how other novel targeted agents affect the management landscape. Finally, Ruan highlights that future studies should focus on optimizing novel agent combinations, such as romidepsin + Lenalidomide or romidepsin + Azacitidine.

 

More about...
Aggressive B-cell lymphomasAngioimmunoblastic T-cell lymphomaAzacitidineBreast implant-associated anaplastic large cell lymphomaBrentuximab vedotinCutaneous T-cell lymphomaEnteropathy-associated T-cell lymphomaEpstein – Barr virus-positive T-cell lymphomaEpstein – Barr virus-positive T-cell lymphoma of childhoodExtranodal NK/T-cell lymphomaFollicular T-cell lymphomaHepatosplenic T-cell lymphomaLenalidomideMature T and NK cell neoplasmsMonomorphic epitheliotropic intestinal T-cell lymphomaPeripheral T-cell lymphomaRomidepsinT-cell/histiocyte-rich large B-cell lymphoma

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Related articles

Add bookmark

Orphan drug designation granted to DT2216 for the treatment of T-cell lymphoma

On March 14, 2022, the U.S. Food and Drug Administration (FDA) granted orphan drug designation to DT2216, a compound based on antiapoptotic protein targeted degradation...

Mar 16, 2022
Add bookmark

Orphan drug designation granted to DT2216 for the treatment of T-cell lymphoma

On March 14, 2022, the U.S. Food and Drug Administration (FDA) granted orphan drug designation to DT2216, a compound...

Mar 16, 2022
Add bookmark

ICML 2019 | How could azacitidine with romidepsin be integrated into the treatment pathway of T-cell lymphomas?

ICML 2019 | How could azacitidine with romidepsin be integrated into the treatment pathway of T-cell lymphomas?

Jun 26, 2019
Add bookmark

ICML 2019 | How could azacitidine with romidepsin be integrated into the treatment pathway of T-cell lymphomas?

ICML 2019 | How could azacitidine with romidepsin be integrated into the treatment...

Jun 26, 2019

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox